Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.61 |
| ▸ | OGA | O60502 | 2/20 | 0.61 |
| ▸ | GOT1 | P17174 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603629 | 0.93 | OGA (0.62) | FAAHOGAGOT1KDM4ECYP1A2 | |
| SCHEMBL3593744 | 0.77 | OGA (0.53) | FAAHOGAGOT1KDM4ECYP1A2 | |
| SCHEMBL3597081 | 0.76 | FAAH (1.00) | FAAHKDM4EMAPT | |
| SCHEMBL20779696 | 0.76 | OGA (1.00) | FAAHOGAMAPTNPC1RAB9A | |
| SCHEMBL20328219 | 0.73 | KDM4E (0.65) | FAAHOGAKDM4ECYP1A2CYP2C9 | |
| SCHEMBL29737208 | 0.71 | KMT2A (0.58) | FAAHKDM4EKMT2APOLBMAPT | |
| SCHEMBL16239936 | 0.70 | NPC1 (0.48) | FAAHKDM4EKMT2AMAOAMAOB | |
| SCHEMBL3597986 | 0.70 | FAAH (1.00) | FAAHKDM4EMAPT | |
| SCHEMBL2897923 | 0.70 | KDM4E (0.77) | FAAHKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10729724 | 0.70 | KDM4E (0.77) | FAAHKDM4ECYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130331396-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-12-12 | — | — | US | claimed |
| US-7598249-B2 | 4-(3,4-dibromo-benzyl)-piperazine-1-carboxylic acid pyridin-3-ylamide; fatty acid amide hydrolase (FAAH) activity; anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders such as multiple sclerosis | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-06 | — | — | US | claimed |
| US-20060173184-A1 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-03 | — | — | US | claimed |
| EP-2937341-A1 | 4-(BENZYL)-PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | Janssen Pharmaceutica N.V. (BE) | 2015-10-28 | — | — | EP | disclosed |
| US-9169224-B2 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-27 | — | — | US | disclosed |
| EP-1836179-B1 | PIPERIDINE- AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | disclosed |
| US-20130331396-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-12-12 | — | — | US | disclosed |
| US-8530476-B2 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-20100004261-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | US | disclosed |
| US-7598249-B2 | 4-(3,4-dibromo-benzyl)-piperazine-1-carboxylic acid pyridin-3-ylamide; fatty acid amide hydrolase (FAAH) activity; anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders such as multiple sclerosis | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-06 | — | — | US | disclosed |
| US-20060173184-A1 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331396-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, USP47 | FAAH 1/4885OGA 2328/4885GOT1 1607/4885 |
| US-20060173184-A1 | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | FAAH, FAAH2, USP47 | FAAH 1/4885OGA 2328/4885GOT1 1607/4885 |
| US-20100004261-A1 | PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, USP47 | FAAH 1/4885OGA 2328/4885GOT1 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.